Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

This study found that a 6-week taper of prednisone led to more than 25% hair regrowth in 30% to 47% of alopecia areata patients, and applying 2% topical minoxidil helped maintain this growth.

This article rebuts a previous rejection of corticosteroid therapy for alopecia areata, reporting successful treatment in multiple patients with systemic and intralesional steroids and minimal side effects.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.

In this case study, a 12-year-old boy with alopecia totalis experienced hair regrowth on the side of his scalp treated with a combination of systemic steroids and dithranol, suggesting a potential synergistic effect that may help manage severe alopecia areata with minimal side effects.

In this observational study conducted in Bengaluru, India, among 272 dermatology patients, the authors reported that dermatitis was the most common condition treated with corticosteroids, with a preference for topical applications; desonide was the most frequently prescribed drug.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

This study found that systemic testosterone exposure in transgender individuals with XX genotype alters skin biology, increasing androgen and estrogen receptor-positive cells, collagen density, and fibronectin expression while reducing immune cells, which could affect surgical outcomes by promoting a male skin phenotype.

This case report highlights that rosacea can be misdiagnosed as systemic lupus erythematosus, with symptom improvement seen after switching from long-term corticosteroid use to topical metronidazole, nicotinamide, and tretinoin.

This case study reports that a woman with systemic lupus erythematosus experienced remission of her symptoms after receiving a combined therapy of corticosteroids and cytostatics.

This paper discusses a consensus statement from European experts recommending systemic JAK inhibitors as first-line therapy for moderate to severe alopecia areata.

Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.

A woman with lupus and antiphospholipid syndrome had bone damage, showing the need for careful treatment.

This review discusses different forms and patterns of alopecia associated with lupus erythematosus and reports no new clinical results; the authors highlight distinct features of these conditions.

This study reports that various types of alopecia, including permanent alopecia, can persist after an acute DRESS episode, but telogen effluvium and alopecia areata showed clinical improvement with treatment within six months.

This study compared serum and hair steroid hormone profiles in adolescents and found that hair steroid profiling is a feasible, non-invasive alternative to serum analysis, with androgen levels in both mediums correlating more strongly with body size and composition in boys than in girls.

This study found that hair steroid profiling is a feasible, non-invasive alternative to serum analysis in adolescents, with androgen levels correlating more strongly with body size and composition in boys than girls.

Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.

This case report highlights a 42-year-old woman with systemic lupus erythematosus who exhibited fundus changes indicating retinal vasculitis, underlining the importance of regular ocular fundus examinations for early detection of severe disease complications.

This study reports that while systemic immunotherapies are often used for immune-mediated hair loss, they may also be considered for treating androgenetic alopecia when it coexists with immune-related conditions like alopecia areata.

This case report documents a 31-year-old woman with bullous SLE who showed improvement with high-dose parenteral steroids and dapsone, with ongoing follow-up due to potential kidney involvement.

This case report details a child with a specific TNFAIP3 mutation manifesting as a severe SLE/SS phenotype, expanding the known phenotype for this genetic variant.

This study presents a case of neuropsychiatric lupus in a 50-year-old woman, highlighting the severe impact on quality of life and the necessity for aggressive treatment to improve outcomes.

This case report describes a patient with systemic sclerosis and severe alopecia areata who experienced complete resolution of hair loss within four months after treatment with topical steroids, minoxidil, and mycophenolate mofetil.

This case report illustrates that Systemic Lupus Erythematosus can lead to severe malabsorption, weight loss, and small bowel inflammation, requiring recognition for effective treatment and improved outcomes.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

This review discusses various systemic diseases associated with secondary alopecia and reports no new clinical findings; it emphasizes the importance of addressing underlying conditions and using diagnostic tools like trichoscopy and histopathology.

This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.

This case report describes a 43-year-old woman diagnosed with both Kikuchi-Fujimoto disease and systemic lupus erythematosus, who showed clinical improvement after treatment with glucocorticoids and hydroxychloroquine, highlighting the rare coexistence of these conditions and the ongoing uncertainty about the precise cause of Kikuchi-Fujimoto disease.

This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.